Immuneering ROA

Que fait Immuneering ? Immuneering Corp. develops oncology medicines for cancer patients with universal-RAS therapy, focusing on the lead product candidate IMM-1-104, currently in Phase I/IIa clinical trials for advanced solid tumors with RAS mutations. The company also develops IMM-6-415, which is in IND stage for universal-MAPK activity with twice-daily dosing, alongside Trifecta MEK, RAS modulators, and other small molecule drug discovery programs. Its platform relies on Bioinformatics and 3D Tumor Modeling to enable drug development. The company generates revenue through clinical-stage product development, targeting cancer treatment markets with novel therapies for RAS-mutated tumors. Immuneering Corp. targets oncology markets with its pipeline of therapies, including IMM-1-104 as a once-daily oral monotherapy and IMM-6-415 with accelerated twice-daily dosing. The company’s development approach centers on deep cyclic inhibition of the MAPK pathway for universal-RAS and universal-MAPK activity. Its product candidates are designed for patients with advanced solid tumors harboring RAS mutations, aiming to address unmet medical needs in cancer treatment through innovative small molecule therapies. The company’s business model involves advancing clinical-stage products through development stages, leveraging Bioinformatics and 3D Tumor Modeling to optimize drug discovery. Revenue is derived from the progression of its pipeline, including IMM-1-104 and IMM-6-415, toward potential market approval. Immuneering Corp. focuses on oncology markets with a clinical-stage approach, targeting RAS-mutated cancer patients through its universal-RAS therapy strategy. Immuneering est l'une des entreprises les plus populaires sur Eulerpool.